<PubmedArticle>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23917222</PMID>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2157-9024</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2</Volume>
<PubDate>
<Year>2013</Year>
<Month>Aug</Month>
<Day>05</Day>
</PubDate>
</JournalIssue>
<Title>Oncogenesis</Title>
<ISOAbbreviation>Oncogenesis</ISOAbbreviation>
</Journal>
<ArticleTitle>Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells.</ArticleTitle>
<Pagination>
<MedlinePgn>e60</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/oncsis.2013.26</ELocationID>
<Abstract>
<AbstractText>The Notch pathway is functionally important in breast cancer. Notch-1 has been reported to maintain an estrogen-independent phenotype in estrogen receptor α (ERα)+ breast cancer cells. Notch-4 expression correlates with Ki67. Notch-4 also plays a key role in breast cancer stem-like cells. Estrogen-independent breast cancer cell lines have higher Notch activity than estrogen-dependent lines. Protein kinase Cα (PKCα) overexpression is common in endocrine-resistant breast cancers and promotes tamoxifen (TAM)-resistant growth in breast cancer cell lines. We tested whether PKCα overexpression affects Notch activity and whether Notch signaling contributes to endocrine resistance in PKCα-overexpressing breast cancer cells.Analysis of published microarray data from ERα+ breast carcinomas shows that PKCα expression correlates strongly with Notch-4. Real-time reverse transcription PCR and immunohistochemistry on archival specimens confirmed this finding. In a PKCα-overexpressing, TAM-resistant T47D model, PKCα selectively increases Notch-4, but not Notch-1, expression in vitro and in vivo. This effect is mediated by activator protein-1 (AP-1) occupancy of the Notch-4 promoter. Notch-4 knockdown inhibits estrogen-independent growth of PKCα-overexpressing T47D cells, whereas Notch-4IC expression stimulates it. Gene expression profiling shows that multiple genes and pathways associated with endocrine resistance are induced in Notch-4IC- and PKCα-expressing T47D cells. In PKCα-overexpressing T47D xenografts, an orally active γ-secretase inhibitor at clinically relevant doses significantly decreased estrogen-independent tumor growth, alone and in combination with TAM. In conclusion, PKCα overexpression induces Notch-4 through AP-1. Notch-4 promotes estrogen-independent, TAM-resistant growth and activates multiple pathways connected with endocrine resistance and chemoresistance. Notch inhibitors should be clinically evaluated in PKCα- and Notch-4-overexpressing, endocrine-resistant breast cancers. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yun</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Cardinal Bernardin Cancer Center and Department of Pathology, Loyola University Chicago, Maywood, IL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pannuti</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Espinoza</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hicks</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Caskey</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rizzo</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>D'Souza</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Backus</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Denning</LastName>
<ForeName>M F</ForeName>
<Initials>MF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Coon</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sun</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bresnick</LastName>
<ForeName>E H</ForeName>
<Initials>EH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Osipo</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Strack</LastName>
<ForeName>P R</ForeName>
<Initials>PR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tonetti</LastName>
<ForeName>D A</ForeName>
<Initials>DA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Miele</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Oncogenesis</MedlineTA>
<NlmUniqueID>101580004</NlmUniqueID>
<ISSNLinking>2157-9024</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2012</Year>
<Month>04</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2013</Year>
<Month>06</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2013</Year>
<Month>06</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2013</Year>
<Month>8</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2013</Year>
<Month>8</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2013</Year>
<Month>8</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">23917222</ArticleId>
<ArticleId IdType="pii">oncsis201326</ArticleId>
<ArticleId IdType="doi">10.1038/oncsis.2013.26</ArticleId>
<ArticleId IdType="pmc">PMC3759125</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Br J Cancer. 1996 Oct;74(8):1227-36</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8883409</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2009 Jun 08;4(6):e5821</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19503789</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2006 Feb 15;12(4):1074-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16489059</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Surg Pathol. 2011 Oct;19(5):607-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20444726</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2359136</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2001 Oct;7(10):3156-65</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11595710</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Growth Differ. 1995 May;6(5):563-77</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7544153</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Cancer. 2001 Dec;1(3):181-93</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11902573</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Genes Dev. 1992 Mar;6(3):345-55</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1372276</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 1997 Apr 24;14(16):1883-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9150355</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Cancer. 2000 Sep;83(6):782-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10952784</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2010 Jan 15;70(2):709-18</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20068161</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mod Pathol. 2007 Jun;20(6):685-93</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17507991</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1997 Jul 25;272(30):18586-94</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9228025</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Mammary Gland Biol Neoplasia. 2001 Jan;6(1):23-36</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11467450</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMC Genomics. 2006 Apr 27;7:96</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16643655</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Clin Pract. 2007 Dec;61(12 ):2051-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17892469</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 2005 Feb;25(4):1458-74</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15684396</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2010 Jan 14;29(2):201-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19838210</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Adv Enzyme Regul. 1984;22:27-55</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6382953</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2007 Dec 20;25(36):5815-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17893378</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Endocrinol. 2003 Feb 28;200(1-2):141-54</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12644307</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 1999 Apr 30;284(5415):770-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10221902</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Cell Biochem. 2006 May 15;98(2):440-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16440325</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 1998 Nov 26;339(22):1609-18</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9828250</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 1993 Apr;8(4):877-86</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8455942</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Pathol. 2007 Nov;60(11):1216-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17965220</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Natl Cancer Inst. 2011 Apr 6;103(7):538-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21447808</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Breast Cancer Res Treat. 2007 Aug;104(2):165-79</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17061041</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Carcinogenesis. 2006 Aug;27(8):1538-46</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16513679</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Cancer. 2006 Jan 15;118(2):290-301</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16080193</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Breast Cancer Res. 2011 Sep 22;13(5):R93</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21939528</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 2007 Mar;27(6):2411-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17220278</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Cell Biol. 2009 Mar 9;184(5):621-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19255248</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Endocr Relat Cancer. 2007 Jun;14(2):293-303</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17639045</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2007 Apr 1;25(10):1239-46</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17401012</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2008 Jul 1;68(13):5226-35</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18593923</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Cancer. 2003 May 6;88(9):1400-2</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12778068</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2007 Oct 1;67(19):9214-20</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17909027</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2008 Jul 1;68(13):5273-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18593928</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Natl Cancer Inst. 2003 Nov 5;95(21):1586-97</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14600091</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Breast Cancer. 2008 Feb;8(1):50-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18501059</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1999 Jan 8;274(2):1124-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9873060</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18490-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19001271</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cancer Res. 2009 Apr;7(4):498-510</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19372579</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2742-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21969591</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMC Cancer. 2012 Oct 06;12:458</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23039365</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2000 Jan 13;19(2):223-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10645000</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2009 Jan 15;28(2):219-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18836481</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 1996 Apr 15;56(8):1775-85</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8620493</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2010 May 20;29(20):2983-95</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20208560</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):145-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15300010</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Radiat Biol. 2009 May;85(5):421-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19437244</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochim Biophys Acta. 1991 Dec 10;1072(2-3):129-57</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1751545</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 2000 Apr 28;275(17):12565-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10777546</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Breast Cancer Res. 2011 Jun 29;13(3):R70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21707964</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2005 Sep 15;65(18):8530-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16166334</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2006 Feb 1;66(3):1517-25</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16452208</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>